Skip to main content

Table 1 Characteristics of NSCLC patients with brain metastasis

From: The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

Characteristics

Total (%)

RCT (%)

RT (%)

P

All patients

238 (100)

129 (100)

109 (100)

 

Gender

 Female

102 (42.9)

60 (46.5)

42 (38.5)

0.22

 Male

136 (57.1)

69 (53.5)

67 (61.5)

 

Smoking

 Never

108 (45.4)

63 (48.8)

45 (41.3)

0.24

 Current/former

130 (54.6)

66 (51.2)

64 (58.7)

 

Age

 ≤60

96 (40.3)

58 (45.0)

38 (35.9)

0.11

 >60

142 (59.7)

71 (55.0)

71 (65.1)

 

Histology

 Adenocarcinoma

227 (95.4)

123 (95.3)

104 (95.4)

0.98

 Non-adenocarcinoma

11 (4.6)

6 (4.7)

5 (4.6)

 

ECOG PS

 0–1

188 (79.0)

101 (78.3)

87 (79.8)

0.77

 2–3

50 (21.0)

28 (21.7)

22 (20.2)

 

Prior chemotherapy

 NO

92 (38.7)

51 (39.5)

41 (37.6)

0.76

 YES

146 (61.3)

78 (60.5)

68 (62.4)

 

Number of BM

 ≤3

65 (27.3%)

33 (25.6%)

32 (29.4%)

0.52

 >3

173 (72.7%)

96 (74.4%)

77 (70.6%)

 

Extracranial metastases

 NO

93 (39.1%)

48 (37.2%)

45 (41.3%)

0.52

 YES

145 (60.9%)

81 (62.8%)

64 (58.7%)

 

Primary disease control

 NO

31 (13.0%)

20 (15.5%)

11 (10.1%)

0.22

 YES

207 (87.0%)

109 (84.5%)

98 (89.9%)

 

RTOG RPA class

 ClassI

50 (21.0%)

31 (24.0%)

19 (17.4%)

0.21

 ClassII + III

188 (79.0%)

98 (76.0%)

90 (82.6%)

 

RTOG GPA grade

 0–2

143 (60.1%)

74 (57.4%)

69 (63.3%)

0.35

 2.5–4

95 (39.9%)

55 (42.6%)

40 (36.7%)

 
  1. Abbreviations: Eastern Cooperative Oncology Group performance status ECOG PS, Brain metastasis BM, the Radiation Therapy Oncology Group RTOG, recursive partitioning analysis RPA, graded prognostic assessment GPA